RegeneRx Biopharmaceuticals, Inc.
OTC: RGRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- J. J. Finkelstein
- Employees
- 2
- Headquarters
- Rockville, United States
- IPO year
- 2003
- Market cap
- $898.0
- Website
- https://www.regenerx.com
Loading RGRX…
Loading profile data…Frequently asked questions about RGRX
What does RegeneRx Biopharmaceuticals, Inc. (RGRX) do?
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore...
Where does RGRX trade?
RegeneRx Biopharmaceuticals, Inc. (RGRX) trades on the Other OTC.
What sector is RGRX in?
RegeneRx Biopharmaceuticals, Inc. (RGRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RegeneRx Biopharmaceuticals, Inc.?
J. J. Finkelstein is the chief executive officer of RegeneRx Biopharmaceuticals, Inc. (RGRX).
Where is RegeneRx Biopharmaceuticals, Inc. headquartered?
RegeneRx Biopharmaceuticals, Inc. is headquartered in United States.
Does RGRX pay a dividend?
RegeneRx Biopharmaceuticals, Inc. (RGRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RGRX go public?
RegeneRx Biopharmaceuticals, Inc. (RGRX) completed its initial public offering in 2003.